Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review discusses evidence from recent clinical trials showing inclisiran effectively lowers LDL cholesterol levels in patients with cardiovascular disease, leading to its use in the UK despite not being approved by the FDA.

In this study, researchers identified nine FDA-approved drugs that activate the Wnt signaling pathway, with Aminoacridine, especially when combined with Minoxidil, showing promising effects on hair and nail growth in mice, suggesting potential treatments for hair and nail loss pending further clinical trials.

This article reviews systemic lupus erythematosus (SLE) and highlights the FDA approval of belimumab, marking the first new SLE treatment in nearly 50 years, but reports no new clinical trial results.

This review discusses the potential benefits of the Restolin Hair Supplement for hair growth and reports no clinical results, with the authors noting that the claims are not supported by FDA approval or clinical trials.

This review discusses the potential of JAK inhibitors as a promising treatment strategy for alopecia areata, highlighting their mechanism and recent FDA approval based on clinical trial efficacy.

This review reports that three JAK inhibitors—baricitinib, ritlecitinib, and deuruxolitinib—have gained FDA approval for treating alopecia areata due to their demonstrated efficacy in fostering hair regrowth in clinical trials.

In June 2019, the stem cell research field saw major progress, including new clinical trials, FDA approvals, and industry collaborations.

Randomized trials reported that testosterone therapy improved sexual function in postmenopausal women with hypoactive sexual desire disorder, particularly those who had undergone oophorectomy, with reversible and well-tolerated side effects.

This article reviews pivotal trials and recent findings in chemoprevention for breast, prostate, and colorectal cancers, emphasizing its potential and the importance of further research, public education, and partnerships, but reports no new results.

This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.

The FDA approved a new breast cancer treatment, found flu shots may reduce heart risks, questioned the safety of fast-tracked drug approvals, showed statins don't help with certain pneumonia, and approved a new dementia imaging agent.

This review analyzed randomized controlled trials on alopecia areata treatment and found that while several treatments showed effectiveness, most studies had limitations affecting their interpretability.

This source reports that clinical trials found oral baricitinib significantly improved hair regrowth in patients with severe alopecia areata, with 38.8% achieving at least 80% scalp hair coverage after 36 weeks on a 4-mg dose, compared to 6.2% with placebo in trial 1.

This abstract outlines a guide reviewing both FDA-approved and off-label therapies for androgenetic alopecia and proposes treatment algorithms based on scientific research, highlighting a gap in common treatments for this prevalent condition.

This article organizes and lists ongoing and completed clinical trials of novel agents for lung cancer, serving as a reference tool with no new research findings reported.

This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.

This narrative review reflects on the challenges faced by FDA's Oncologic Drugs Advisory Committee members, highlighting public pressure, decision-making complexity, and the evolving landscape of cancer drug development.

This study reported that dupilumab, an FDA-approved biologic, is a safe and effective first-line systemic treatment for children with moderate-to-severe atopic dermatitis, showing sustained skin improvement and itch reduction, with injection site reactions and conjunctivitis as potential side effects.

This review discusses the pathophysiology of androgen-stimulated skin disorders and key clinical trials of 5α-reductase inhibitors for their treatment, but it does not report new clinical results.

This abstract discusses finasteride and dutasteride's mechanisms in treating androgenetic alopecia and notes FDA approval for finasteride, but reports no new clinical results.

This study found that among ten identified medications associated with ejaculatory disorders, Paroxetine and Tamsulosin were mainly linked to delayed and retrograde ejaculation, while Finasteride and Sildenafil were most associated with painful ejaculation and ejaculation failure according to reports from FDA-FAERS and Eudra-Vigilance databases.

This study reviewed baricitinib's efficacy and safety for treating alopecia areata and found that more patients achieved significant hair regrowth with baricitinib compared to placebo in two phase III trials. Mild to moderate side effects were reported, with additional study suggested for long-term effects.

This study reported that clascoterone cream reduced inflammatory and noninflammatory acne lesions in a trial with 1440 white males and non-pregnant females, showing it was well tolerated in these participants.

More men are using medication for benign prostatic hyperplasia, influenced by marketing and FDA approvals.

This study discusses how emerging biologics and small molecule therapies could enhance disease management and pediatric health outcomes for chronic skin conditions, suggesting their potential inclusion in treatment guidelines pending ongoing clinical trial successes.

This review discusses the role of toll-like receptors in cancer treatment, providing an overview of pre-clinical studies and clinical trials on TLR-targeted therapies and noting the challenges and future prospects.

This review highlights bicalutamide as a promising oral therapy for female pattern hair loss, noting its safety, tolerability, and effectiveness in women with hyperandrogenic symptoms like acne and hirsutism, though further trials are needed to confirm its ideal dose and efficacy.

This article reviews various hair growth and hair loss treatments, noting limited new developments since FDA-approved drugs but highlights recent cosmetic surgery and potential cell-based therapies; it reports no original findings.

This review highlights the potential of nanocarriers, like liposomes and solid lipid nanoparticles, in improving targeted drug delivery and effectiveness for androgenetic alopecia treatment, while noting the hurdles of clinical trials and regulatory approval for these advanced methods.

This review discusses the potential of nanocarriers like liposomes and nanoparticles to enhance the delivery and efficacy of treatments for androgenetic alopecia, while noting the challenges of clinical translation, such as securing reliable trials and regulatory approval.